Andrew vaccines Fina BioSolutions LLC Biography Publications Institution JoVE Articles Andrew Andrew Lees is founder and scientific director of Fina Biosolutions LLC (Rockville, MD), a company focused on promoting affordable conjugate vaccines by making the technology available to emerging market vaccine manufacturers. Among his contributions in the field, Andrew developed an efficient linking chemistry which is widely used in conjugate vaccines, a class that includes vaccines for S. pneumoniae and meningococcal disease. The chemistry has helped to reduce the cost of these vaccines. Prior to starting Fina Biosolutions in 2006, he was Director of Vaccine Development at biotech companies Virion Systems (1993-1999) and Biosynexus (1999-2006). He was also an associate research professor at the Uniformed Services University (1993-1999). Andrew is an professor at the University of Maryland School of Medicine Center for Vaccine Development, the Uniformed Services University, Dept. of Medicine and the University of Toledo, Dept of Chemistry. He has over 70 publications and 25 patents, mainly in the area of conjugate vaccines. He received his BS in chemistry from Harvey Mudd College in chemistry (1976) and his Ph.D. in Biophysics from Johns Hopkins (1984). Honors include the Uniformed Services Meritorious Service Award, Harvey Mudd College Outstanding Alumni Award and is a Johns Hopkins University Outstanding Alumni. On graduating from Hopkins, he was on the cover of Baltimore Magazine as one of “84 people to watch in ‘84”, due to his role as a leading Baltimore area magician. Publications Activation of Soluble Polysaccharides with 1-Cyano-4-Dimethylaminopyridine Tetrafluoroborate (CDAP) for Use in Protein-Polysaccharide Conjugate Vaccines and Immunological Reagents. III Optimization of CDAP Activation Vaccines. Dec, 2020 | Pubmed ID: 33353255 Comparison of Carrier Proteins to Conjugate Malaria Transmission Blocking Vaccine Antigens, Pfs25 and Pfs230 Vaccine. 07, 2020 | Pubmed ID: 32600913 Immunogenicity and Induction of Functional Antibodies in Rabbits Immunized with a Trivalent Typhoid-Invasive Nontyphoidal Glycoconjugate Formulation Molecules (Basel, Switzerland). Jul, 2018 | Pubmed ID: 30018230 Analytical Comparability Assessments of 5 Recombinant CRM Proteins From Different Manufacturers and Expression Systems Journal of Pharmaceutical Sciences. 07, 2018 | Pubmed ID: 29526446 Immunization of Cows with Novel Core Glycolipid Vaccine Induces Anti-endotoxin Antibodies in Bovine Colostrum Vaccine. Oct, 2014 | Pubmed ID: 25242628 Correlation of Group C Meningococcal Conjugate Vaccine Response with B- and T-lymphocyte Activity PloS One. Month, 2012 | Pubmed ID: 22347446 The Nature of an in Vivo Anti-capsular Polysaccharide Response is Markedly Influenced by the Composition And/or Architecture of the Bacterial Subcapsular Domain Journal of Immunology (Baltimore, Md. : 1950). Jan, 2012 | Pubmed ID: 22156342 Functional T-cell Deficiency in Adolescents Who Experience Serogroup C Meningococcal Disease Despite Receiving the Meningococcal Serogroup C Conjugate Vaccine Clinical and Vaccine Immunology : CVI. Jul, 2010 | Pubmed ID: 20463106 Evidence of a Functional B-cell Immunodeficiency in Adults Who Experience Serogroup C Meningococcal Disease Clinical and Vaccine Immunology : CVI. May, 2009 | Pubmed ID: 19279166 Activation et conjugaison de polysaccharides solubles à l’aide de tétrafluoroborate de 1-cyano-4-diméthylaminopyridine (CDAP) Andrew Lees1, James Zhou1 1Fina Biosolutions LLC JoVE 62597 Immunology and Infection
Activation et conjugaison de polysaccharides solubles à l’aide de tétrafluoroborate de 1-cyano-4-diméthylaminopyridine (CDAP) Andrew Lees1, James Zhou1 1Fina Biosolutions LLC JoVE 62597 Immunology and Infection